| |
The significant scientific capabilities of local talent, infrastructure and the island's decades of expertise fuel MBQ Pharma's advancement of innovative treatments for solid tumor cancers. Learn how your business can also impact the bioscience industry in Puerto Rico. .png)
|
|
Today’s Big NewsJun 21, 2024 |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
| By Kevin Dunleavy The FDA has expanded the label for Sarepta's Elevidys to all Duchenne muscular dystrophy patients ages 4 and older. It’s a major boost for the first gene therapy to treat the inherited disorder, which received an accelerated approval a year ago—nearly to the date—but only for ambulatory boys ages 4 to 5. |
|
|
|
By Nick Paul Taylor Zealand Pharma is lining up a challenge to its compatriot Novo Nordisk. The Danish biotech’s CEO said obesity candidate petrelintide can be “the backbone of therapy for weight management” after reporting phase 1b data that suggest it may provide GLP-1-like efficacy without the side effects. |
By Andrea Park Data released earlier this month showed that across nearly 600 cancer patient groups, Roche was rated as having the best reputation among pharmas. Now, PatientView has offered an even deeper dive into those findings, breaking out patient sentiments by several cancer types. |
By Conor Hale Using a version of OpenAI’s GPT-4 program, the AI quickly combed through doctors' notes and identified patients with heart failure who met study criteria. |
By Fraiser Kansteiner Cystic fibrosis (CF) patients and their families in England can rest a little easier this week, thanks to an extended long-term reimbursement deal inked by Vertex Pharmaceuticals and the country’s National Health Service (NHS). |
By Zoey Becker The med is the first new chemical entity to win FDA approval specifically to treat primary axillary hyperhidrosis, or excessive underarm sweating. It's also Botanix's first approved product. |
By James Waldron Switzerland’s Melodia Therapeutics has signed a $275 million biobucks deal to get its hands on Alivexis’ preclinical cathepsin C inhibitor. |
By Conor Hale The OmnifyXR system includes a wearable heads-up display capable of showing up to four different information feeds at once. |
By Nick Paul Taylor “Persistent and severe misconduct” by pharma companies in the U.K. shows the inadequacy of existing self-regulation of marketing, according to researchers who analyzed complaints from 2004 to 2021. |
By Fraiser Kansteiner Amid an influx of efforts to help the African continent claim vaccine sovereignty, a new financing mechanism devised by Gavi, the Vaccine Alliance, the African Union and the Africa Centres for Disease Control and Prevention (Africa CDC) has taken flight. |
By Gabrielle Masson,Andrea Park,Fraiser Kansteiner Third Rock Ventures’ Marea has unveiled with $190 million and Josh Lehrer, M.D., in the top spot. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” Fierce Pharma’s Zoey Becker sits down with Bobby Sheng, the CEO of Bora Pharmaceuticals, to discuss the concept of “friend-shoring” in drug manufacturing. |
|
|---|
|
|
|
Wednesday, June 26, 2024 | 2pm ET/ 11am PT In this webinar, we outline a patient-centered telehealth genetic counseling model that accelerates time to meet recruitment goals by engaging and recruiting genetically eligible participants. Certified genetic counselors are uniquely qualified to support the development of a multi-phased approach to patient identification and screening, disclose genetic test results, and more. Register now. 
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
